ERBB2 and neoplasm: To address this, studies have conjugated anti-CD16 nanobodies to nanobodies targeting CEA (119–122), MUC-1 (123), HER2 (124), or to Fabs targeting HER2 (125, 126) or GPC3 (127), with potent tumor growth suppression in vivo.